Taysha Gene Therapies Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
TSHA$4.37+0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows
(in thousands)
| For the Nine MonthsEnded September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(70,513) | $(159,307) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 941 | 1,005 |
| Stock-based compensation | 9,887 | 5,937 |
| Research and development license expense | — | 3,500 |
| Change in fair value of warrant liability | 67 | 100,456 |
| Issuance costs for pre-funded warrant liability | — | 2,567 |
| Non-cash change in fair value of term loan | 135 | — |
| Impairment of long-lived assets | 4,838 | 616 |
| Non-cash lease expense | 916 | 908 |
| Other | 678 | 581 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (612) | 4,008 |
| Accounts payable | (1,416) | (1,065) |
| Accrued expenses and other liabilities | (1,527) | (4,260) |
| Deferred revenue | (6,311) | (11,847) |
| Net cash used in operating activities | (62,917) | (56,901) |
| Cash flows from investing activities | ||
| Purchase of research and development license | — | (3,500) |
| Purchase of property, plant and equipment | (376) | (3,852) |
| Other | — | 10 |
| Net cash used in investing activities | (376) | (7,342) |
| Cash flows from financing activities | ||
| Debt issuance costs for term loan | (18) | — |
| Proceeds from issuance of common stock and pre-funded warrants from underwritten public offering, net of underwriting discounts and sales commissions and other offering costs | 77,140 | — |
| Proceeds from issuance of common stock and pre-funded warrants from private placement, net of placement agent commissions and other offering costs | — | 140,713 |
| Proceeds from issuance of common stock from private placement | — | 500 |
| Payment of shelf registration costs | — | (387) |
| Proceeds from common stock issuances under ESPP | 89 | 68 |
| Other | (170) | (253) |
| Net cash provided by financing activities | 77,041 | 140,641 |
| Net increase in cash, cash equivalents and restricted cash | 13,748 | 76,398 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 146,540 | 90,517 |
| Cash, cash equivalents and restricted cash at the end of the period | $160,288 | $166,915 |
| Cash and cash equivalents | 157,688 | 164,278 |
| Restricted cash | 2,600 | 2,637 |
| Cash, cash equivalents and restricted cash at the end of the period | $160,288 | $166,915 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $3,980 | $3,665 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Issuance of warrants in connection with private placement | — | 252 |
| Property, plant and equipment in accounts payable and accrued expenses | 133 | 45 |
| Offering costs not yet paid | 360 | 423 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.